AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Enlivex to present Allocetra's therapeutic potential in inflammatory diseases at Israeli BioMed 2025 Conference.
ByAinvest
Tuesday, May 20, 2025 8:20 am ET1min read
Enlivex Therapeutics has been selected to present at the Israeli BioMed 2025 Conference. The company's CEO will deliver a presentation titled "Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases". Enlivex's Allocetra cell therapy is designed to reset macrophages to their homeostatic state, addressing chronic and life-threatening inflammatory diseases.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) has been selected to present at the upcoming Israeli BioMed 2025 Conference, scheduled from May 21 to 23 in Tel Aviv, Israel. The company's CEO will deliver a presentation titled "Enlivex—Harnessing the Natural Healing Power of Macrophages to Treat Inflammatory Diseases" as part of the session "Personalized Pathways; Genetic and Cellular Based Therapies for Rare and Complex Diseases" [1].Enlivex is a clinical-stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This therapy aims to address chronic and life-threatening inflammatory diseases by resetting non-homeostatic macrophages [1].
The company's presentation will highlight Allocetra™'s therapeutic potential in inflammatory diseases. Preliminary data from a six-month interim readout in moderate knee osteoarthritis showed statistically significant reductions in pain (47%), improvement in joint function (46%), and decrease in stiffness (40%) [1]. Enlivex is currently advancing a broad clinical pipeline with Allocetra™, including multiple Phase I/II trials in osteoarthritis and psoriatic arthritis, with additional readouts expected in 2025 [1].
Enlivex's approach to macrophage reprogramming offers a promising strategy for immune system rebalancing and disease resolution. The company's presentation at the Israeli BioMed 2025 Conference will provide insights into the potential of Allocetra™ in treating inflammatory diseases, positioning Enlivex as a leader in the field of macrophage reprogramming immunotherapy [1].
References:
[1] https://www.marketscreener.com/quote/stock/ENLIVEX-THERAPEUTICS-LTD-56422776/news/Enlivex-Selected-to-Present-at-Israeli-BioMed-2025-Conference-50010352/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet